TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7068935
Drug: Erythromycin ethylsuccinate
Normalized name: Erythromycin Ethylsuccinate
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin ethylsuccinate (250 mg, four times a day for six days)
Study: 7068935
Drug: Lactose placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose placebo (control group, 250 mg, four times a day for six days)
Study: 4061890
Drug: Tamoxifen 20
Normalized name: tamoxifen 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 20 mg/day (n = 20)
Study: 27956763
Drug: Oral immunonutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral immunonutrition (IN)
Study: 27956763
Drug: Oral standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral standard nutrition (Control)
Study: 24783221
Drug: Ultrarush therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrarush therapy
Study: 22212646
Drug: 1500 μg
Normalized name: flunixin
DrugBank: Flunixin (DB11518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 μg vitamin D₃ (group 1)
Study: 22212646
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of 3000 μg vitamin D₃ (group 2)
Study: 20974030
Drug: Belladonna and
Normalized name: BELLADONNA AND DERIVATIVES, PLAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belladonna and opium (B & O) suppository
Study: 15605190
Drug: Clodronate (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate (800 mg daily for 2 years)
Study: 12408892
Drug: Nefopam (NEF)
Normalized name: nefopam
DrugBank: Nefopam (DB12293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam (NEF) and desmethyl-nefopam (DMN) assayed using HPLC with a mobile phase of buffer and acetonitrile, flow rate 1.5 ml/min.
Study: 7573921
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (EM/LIG) - EMLA and intradermal and subdermal 1% lignocaine infiltration
Study: 7573921
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C (PL/LIG) - Placebo cream and 1% lignocaine
Study: 1976549
Drug: Lamicel tent
Normalized name: Lamictal
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamicel tent preoperative treatment
Study: 7283035
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no topical hydrogen peroxide)
Study: 31379101
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of teriflunomide
Study: 31379101
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of teriflunomide
Study: 30072191
Drug: Nab-paclitaxel (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nab-paclitaxel (100 mg/m2) followed by FEC
Study: 26822209
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg melatonin administered for 7 consecutive days
Study: 26822209
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo administered for 7 consecutive days
Study: 24961471
Drug: 4 ml
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml of human fibrin sealant (Tisseel™, Baxter(®) Deerfield, IL, USA) sprayed along the suture line
Study: 22146491
Drug: Antivenom B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antivenom B (whole IgG molecules)
Study: 18198641
Drug: Aidi Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aidi Injection (ADI) combined with FOLFOX4 regimen
Study: 10673673
Drug: Mobilization chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobilization chemotherapy
Study: 3519766
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg hydrochlorothiazide twice daily for 4 weeks
Study: 30125353
Drug: Ivermectin 300
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin 300 mcg/kg/day plus Dihydroartemisinin-Piperaquine (DP)
Study: 30125353
Drug: Ivermectin 600
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin 600 mcg/kg/day plus Dihydroartemisinin-Piperaquine (DP)
Study: 30125353
Drug: Ivermectin 0
Normalized name: ivermectin 0.136 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin 0 mcg/kg/day plus Dihydroartemisinin-Piperaquine (DP)
Study: 30125353
Drug: Ivermectin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin (all doses)
Study: 25945337
Drug: Liothyronine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liothyronine (50 mcg every morning)
Study: 23432361
Drug: Melatonin 3
Normalized name: melatonin 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 3 mg day(-1)
Study: 16533938
Drug: Abciximab (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abciximab (0.25 mg/kg bolus, followed by 0.125 microg/kg/min infusion for 12 hours, plus heparin, 70 U/kg)
Study: 16533938
Drug: Placebo (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (placebo bolus and infusion for 12 hours, plus heparin bolus, 140 U/kg)
Study: 9059953
Drug: Cyclical etidronate
Normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cyclical etidronate (400 mg daily for 2 weeks) + calcium (500 mg daily for 11 weeks)
Study: 29528986
Drug: Quadrivalent human
Normalized name: PAPILLOMAVIRUS HUMAN QUADRIVALENT VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent human papillomavirus vaccine (qHPV; types 6, 11, 16, 18)
Study: 25634117
Drug: Intravenous nicorandil
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nicorandil (4-12 mg/h)
Study: 21371155
Drug: Nicotine replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine replacement therapy (NRT) with a selection box containing patch, gum, inhaler, sublingual tablet, oral pouch for 8 weeks after a week of familiarization.
Study: 2898045
Drug: Intranasal glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intranasal glucagon (7.5 mg)
Study: 30950580
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg Lutein and Zeaxanthin (L+Z)
Study: 27925283
Drug: Haloperidol (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (4 mg oral dose)
Study: 23549100
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab and dexamethasone combination therapy (Group 1)
Study: 23549100
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab monotherapy (Group 2)
Study: 19554090
Drug: Intensive statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive statin therapy aiming for LDL-cholesterol levels below 70 mg/dL
Study: 19554090
Drug: Standard statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard statin therapy aiming for LDL-cholesterol levels < or =100 mg/dL
Study: 15199111
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (1200 mg/day)
Study: 11748341
Drug: Etidronate therapy
Normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etidronate therapy (discontinued after 52 weeks)
Study: 11748341
Drug: Calcium alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium alone (500 mg/d)
Study: 7751528
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (vehicle)
Study: 106963
Drug: Oral nonabsorbable
Normalized name: COLLAGEN HEMOSTAT,ABSORBABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nonabsorbable antibiotics plus isolation
Study: 24888857
Drug: Oral antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antibiotics alone
Study: 31151076
Drug: Topical human
Normalized name: thrombin topical human topical solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical human platelet lysate
Study: 31151076
Drug: Topical Clobetasol
Normalized name: clobetasol Topical Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Clobetasol Propionate
Study: 28093041
Drug: ISM1/BlastAssist (sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISM1/BlastAssist (sequential media)
Study: 22018220
Drug: Iloprost in
Normalized name: iloprost Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iloprost in saline solution for three weeks
Study: 19583077
Drug: Manual injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual injection of 0.3 ml/kg lidocaine 0.5%
Study: 19583077
Drug: Automatic pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automatic pump injection of 0.3 ml/kg lidocaine 0.5%
Study: 16754920
Drug: 125 mL
Normalized name: 125 ML argatroban 1 MG/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mL of coffee (200 mg of caffeine)
Study: 16754920
Drug: Placebo (decaffeinated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (decaffeinated coffee containing 15 mg of caffeine)
Study: 2964080
Drug: Distilled water
Normalized name: Distilled Water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distilled water (400 ml at room temperature)
Study: 2964080
Drug: Distilled water
Normalized name: Distilled Water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distilled water (400 ml at 4 degrees C)
Study: 28656452
Drug: Medication Adherence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication Adherence Rating Scale (MARS)
Study: 28656452
Drug: First-generation antipsychotic
Normalized name: benzethonium chloride / lidocaine hydrochloride Topical Gel [Tecnu First Aid]
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-generation antipsychotic use
Study: 23782410
Drug: Vapotherm 2000i
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vapotherm 2000i at 7 L/min
Study: 23782410
Drug: Fisher &
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fisher & Paykel HHHFNC at 7 L/min
Study: 23782410
Drug: Vapotherm 2000i
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vapotherm 2000i at 8 L/min
Study: 23782410
Drug: Fisher &
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fisher & Paykel HHHFNC at 8 L/min
Study: 14634878
Drug: Stereotactic aspiration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic aspiration and fibrinolysis with 3 mg rTPA
Study: 14634878
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment according to best medical treatment
Study: 8779363
Drug: Oral benzocaine
Normalized name: benzocaine Oral Paste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral benzocaine 20 mg
Study: 8779363
Drug: Lignocaine 100
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine 100 mg sprayed onto vocal cords
Study: 8779363
Drug: Nebulised lignocaine
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised lignocaine 4 ml (4%)
Study: 11239030
Drug: Loop diuretics
Normalized name: LOOP DIURETICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loop diuretics (torasemide or frusemide), 3 mg/kg body weight i.v. every 6 h
Study: 9519355
Drug: Maximal androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximal androgen blockade (goserelin acetate 3.6 mg s.c. once every 4 weeks + flutamide 250 mg 3 x daily)
Study: 3143576
Drug: Ciprofloxacin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (1 g for seven days)
Study: 15667660
Drug: Doxycycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (100 mg)
Study: 31615840
Drug: Doxycycline (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (200 mg)
Study: 27851679
Drug: Telephone follow-up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone follow-up (TFU) 4 and 14 days after discharge in addition to conventional treatment
Study: 22428572
Drug: All-purpose nipple
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All-purpose nipple ointment (APNO)
Study: 19120717
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil (OM) 20 mg/d, up-titrated to 40 mg/d, then OM/HCTZ 40/12.5 mg/d, and OM/HCTZ 40/25 mg/d
Study: 16373084
Drug: TACO (600-1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: TACO (600-1200 mg DSM)
Study: 10936148
Drug: Lidocaine inhalation
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine inhalation (5 mg/kg)
Study: 10936148
Drug: Salbutamol inhalation
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol inhalation (1.5 mg)
Study: 10936148
Drug: Combined lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined lidocaine and salbutamol inhalation
Study: 3904806
Drug: Short contact
Normalized name: BenzePrO Short Contact 9.8 % Topical Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short contact therapy with 1%, 2%, and 3% dithranol (30 min)
Study: 3904806
Drug: Overnight therapy
Normalized name: Systane Overnight Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overnight therapy with 1%, 2%, and 3% dithranol
Study: 29997136
Drug: Alitretinoin 30
Normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alitretinoin 30 mg once daily
Study: 24336915
Drug: Topical ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ketorolac tromethamine, 0.45% (Acuvail), 4 times daily for 3 days before surgery
Study: 10754614
Drug: Prophylactic antiemetic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antiemetic therapy (any active treatment)
Study: 1425820
Drug: Selegiline (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline (10 mg/day) alone or in combination with tocopherol
Study: 3904132
Drug: Continuous administration
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous administration of Estracyt
Study: 3904132
Drug: Intermittent administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent administration of Estracyt
Study: 26296954
Drug: Guadecitabine 60
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Guadecitabine 60 mg/m(2) daily × 5
Study: 26296954
Drug: Guadecitabine 90
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Guadecitabine 90 mg/m(2) daily × 5
Study: 26296954
Drug: Guadecitabine (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guadecitabine (various doses)
Study: 21555686
Drug: Axitinib plus
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Axitinib plus docetaxel (docetaxel 80 mg/m2 once every 3 weeks plus axitinib 5 mg twice per day)
Study: 21555686
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus docetaxel (docetaxel 80 mg/m2 once every 3 weeks plus placebo)
Study: 16931508
Drug: Cabergoline (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline (2 mg single evening dose)
Study: 10833188
Drug: 500 ml
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml bottle
Study: 9061387
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol (100 micrograms every 3 hours)
Study: 4032272
Drug: 4 X
Normalized name: Mepilex AG 4 x 4"
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 X 100‐mg chewable tablets chewed before swallowing (CHEW)
Study: 4032272
Drug: 2 X
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 X 200‐mg conventional tablets (CT)
Study: 4032272
Drug: 4 X
Normalized name: Mepilex AG 4 x 4"
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 X 100‐mg chewable tablets swallowed whole (SW)
Study: 4032272
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg b.i.d. (projected steady-state)
Study: 4032272
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg b.i.d. (steady state)
Study: 17588301
Drug: Prolonged-release nicotinic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged-release nicotinic acid (Niaspan) at a maximum dose of 2000 mg/day
Study: 2339081
Drug: Intravenous cholecystography
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cholecystography
Study: 373995
Drug: Indoprofen 600
Normalized name: Neoprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indoprofen 600 mg daily
Study: 31111678
Drug: ramucirumab as
Normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ramucirumab as a single agent
Study: 31111678
Drug: apatinib as
Approvals — FDA: no, EMA: no, PMDA: no
Description: apatinib as a third-line or later treatment
Study: 31111678
Drug: ramucirumab plus
Normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ramucirumab plus immune checkpoint inhibitors
Study: 31111678
Drug: apatinib in
Normalized name: Product containing lapatinib in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: apatinib in combination with cytotoxic agents
Study: 30518584
Drug: Establishment of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Establishment of a trauma treatment team in the experimental group
Study: 30518584
Drug: Basic treatments
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic treatments in both experimental and control groups
Study: 29908775
Drug: Insulin resistance
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin resistance (measured by HOMA-IR)
Study: 15470334
Drug: Nitroflurbiprofen (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroflurbiprofen (100 mg)
Study: 15470334
Drug: Flurbiprofen (65
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen (65 mg)
Study: 12042232
Drug: Nefazodone 400-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefazodone 400-600 mg/day
Study: 1688499
Drug: Intravenous gammaglobulin
Normalized name: Human gammaglobulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous gammaglobulin (IV‐IgG) at a dose of 400 mg/kg for 5 days
Study: 31383945
Drug: Surface measurement
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surface measurement (SM) method among BW < 1000 g
Study: 31383945
Drug: Birth weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Birth weight (BW) method among BW < 1000 g
Study: 31694493
Drug: Normal-weight central
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal-weight central obesity measured by subcutaneous fat thickness
Study: 27522981
Drug: Autologous platelet
Normalized name: AUTOLOGOUS PLATELET RICH PLASMA
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous platelet gel
Study: 27522981
Drug: Antiseptic ointment
Normalized name: Listerine Antiseptic
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiseptic ointment dressing
Study: 25844614
Drug: HSP infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HSP infusion head
Study: 23637110
Drug: Joint crisis
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Joint crisis plan in addition to treatment as usual (TAU)
Study: 22922860
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron (iron fumarate)
Study: 15724865
Drug: Magnesium therapy
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium therapy (Magne B(6)R, Sanofi‐Synthelabo)
Study: 7485860
Drug: Topical ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical ciprofloxacin (0.3%)
Study: 8924287
Drug: Topical gentamicin
Normalized name: gentamicin Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical gentamicin (0.3%)
Study: 2404660
Drug: Combined pharmacotherapy
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined pharmacotherapy plus cognitive-behavioral psychotherapy
Study: 7197978
Drug: Amezinium 10
Normalized name: amezinium 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amezinium 10 mg i.v.
Study: 7197978
Drug: Amezinium (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amezinium (various p.o. doses)
Study: 7197978
Drug: Norfenefrine 10
Normalized name: norfenefrine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfenefrine 10 mg i.m. and 40 mg p.o.
Study: 7197978
Drug: Dihydroergotamine 1
Normalized name: DIHYDROERGOTAMINE 1MG/ML INJ AMP 1ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroergotamine 1 mg i.m. and 4 mg p.o.
Study: 31699131
Drug: Combined group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined group (15 mg/kg IV-TXA + 2 g topical TXA)
Study: 31699131
Drug: IV group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV group (15 mg/kg IV-TXA)
Study: 28081719
Drug: Antibiotic Prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic Prophylaxis (AP) continued
Study: 28081719
Drug: Antibiotic Prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic Prophylaxis (AP) stopped
Study: 17150319
Drug: Chios mastic
Normalized name: Thymus mastichina flowering top oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chios mastic powder (5g daily, high-dose group)
Study: 17150319
Drug: Chios mastic
Normalized name: Thymus mastichina flowering top oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chios mastic solution (low-dose group)
Study: 15522140
Drug: Dried garlic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dried garlic powder tablets (10.8 mg alliin/d, corresponding to about three garlic cloves)
Study: 29987109
Drug: Sitagliptin 100
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 100 mg/d plus valsartan 160 mg/d
Study: 25019209
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of RSV